Septerna (NASDAQ:SEPN) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Septerna (NASDAQ:SEPN) from a hold rating to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

A number of other equities research analysts have also recently commented on the company. Raymond James Financial restated a “strong-buy” rating and set a $49.00 target price on shares of Septerna in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Thursday, October 15th. JPMorgan Chase & Co. upped their price target on Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a report on Wednesday, August 19th. Stifel Nicolaus increased their price target on Septerna from $49.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, November 10th. Finally, Guggenheim raised their price objective on Septerna from $51.00 to $65.00 and gave the company a “buy” rating in a report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $56.44.

Septerna Price Performance

SEPN stock traded up $0.74 during midday trading on Friday, hitting $42.60. 337,791 shares of the stock traded hands, compared to its average volume of 421,986. The firm has a market cap of $2.03 billion, a P/E ratio of -33.02 and a beta of 2.20. The stock’s fifty day simple moving average is $40.46 and its 200-day simple moving average is $33.12. Septerna has a 1-year low of $19.69 and a 1-year high of $53.34.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15). The firm had revenue of $18.88 million during the quarter, compared to analysts’ expectations of $20.78 million. Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%. On average, research analysts predict that Septerna will post -1.45 earnings per share for the current year.

Insider Activity at Septerna

In other Septerna news, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $37.41, for a total value of $149,640.00. Following the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $6,517,158.69. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Alan Ezekowitz sold 81,820 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $48.09, for a total transaction of $3,934,723.80. Following the completion of the transaction, the director directly owned 35,600 shares in the company, valued at $1,712,004. This trade represents a 69.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 89,153 shares of company stock valued at $4,210,451. Corporate insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Septerna

A number of large investors have recently made changes to their positions in the stock. Checkpoint Capital L.P. acquired a new stake in shares of Septerna in the third quarter valued at approximately $2,504,000. State Board of Administration of Florida Retirement System purchased a new position in Septerna during the third quarter worth approximately $232,000. First Trust Advisors LP lifted its position in Septerna by 129.4% during the third quarter. First Trust Advisors LP now owns 17,750 shares of the company’s stock worth $695,000 after buying an additional 10,011 shares in the last quarter. Voya Investment Management LLC purchased a new position in Septerna during the third quarter worth approximately $565,000. Finally, Russell Investments Group Ltd. lifted its position in Septerna by 8.6% during the third quarter. Russell Investments Group Ltd. now owns 43,683 shares of the company’s stock worth $1,709,000 after buying an additional 3,474 shares in the last quarter.

More Septerna News

These are some of the SEPN news items that stood out recently:

• Positive Sentiment: Analysts raised expectations for Septerna’s SEP-479 program, prompting a fair-value increase. The more optimistic outlook could support investors’ expectations for the company’s pipeline. Septerna fair-value lift as analysts raise SEP-479 expectations
• Positive Sentiment: Stifel Nicolaus raised its price target on SEPN, while another report said the shares reached a new 52-week high following an analyst upgrade—signals that may reinforce positive sentiment. Stifel Nicolaus price-target boost Shares reach a 52-week high following analyst upgrade
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $60 target. Its revisions were mixed: it raised its FY2027 loss estimate to a smaller loss of $1.34 per share, but lowered its FY2026 estimate to a larger loss of $1.48 per share and also cut estimates for Q4 2026 and Q1 2027. Septerna analyst and stock information

Septerna Company Profile

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.